BA-Merrill Lynch 13/11/2009 1 Buy, Medium Risk $38.90 22.7%
The broker notes some conflicting views as to the state of the blood fractionators market implies some risk of a downward shift in prices, reflecting recent increased inventory levels in the wholesaling market.
There are no changes to its forecasts or rating, the broker merely highlighting this as an issue to watch in coming weeks/months.
BA-Merrill Lynch 13/11/2009 1 Buy, Medium Risk $38.90 22.7%The...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$295.21 |
Change
0.050(0.02%) |
Mkt cap ! $142.6B | |||
| Open | High | Low | Value | Volume |
| $296.30 | $298.20 | $295.00 | $229.6M | 780.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 248 | $295.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $295.21 | 42 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CSL (ASX) Chart |